Adicet Bio (NASDAQ:ACET) has appointed Julie Maltzman, MD, as chief medical officer (CMO), effective January 13, 2025. Adicet reports that Dr. Maltzman succeeds Dr. Francesco Galimi, who has completed his tenure with...
Silo Pharma (NASDAQ:SILO) has announced the initiation of a preclinical pharmacokinetic (PK) and tolerability study, in partnership with AmplifyBio, to assess Silo’s dissolvable, ketamine-based injectable implant, SP-26...
Larimar Therapeutics (NASDAQ:LRMR) has announced positive initial results from its ongoing open-label extension (OLE) study evaluating daily subcutaneous injections of 25 mg of nomlabofusp, either self-administered or...
KalVista Pharmaceuticals (NASDAQ:KALV) has announced that Jeb Ledell has been appointed as chief operating officer (COO). Mr. Ledell brings more than 20 years of leadership and operational excellence in the...
MindMed (NASDAQ:MNMD) has announced that the first patient has been dosed in its Phase 3 Voyage study of MM120, an orally disintegrating tablet (ODT) and pharmaceutically optimized form of LSD, in generalized anxiety...
Fractyl Health (NASDAQ:GUTS) has announced that it will present new data from its RJVA-001 Rejuva Smart GLP-1 pancreatic gene therapy program for the treatment of obesity and type 2 diabetes (T2D) at the 22nd World...
Rockwell Medical (NASDAQ:RMTI) announced the promotion of Jesse Neri to chief financial officer (CFO). Mr. Neri, formally Rockwell’s senior vice president of finance, joined the company in 2023, bringing more than 25...
Analysts Kaveri Pohlman, PhD and Bill Maughan, PhD from Clear Street, a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, have launched coverage of several healthcare names. “The...
Candel Therapeutics (NASDAQ:CADL) has announced results from its multicenter Phase 3 trial evaluating CAN-2409 viral immunotherapy in patients with localized prostate cancer. The study achieved its primary endpoint...
Closely held PharmaJet has announced that the peer-reviewed journal Nature has published findings from a U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Phase 1 trial, demonstrating that the...
Akoya Biosciences (NASDAQ:AKYA) announced that it has entered into an exclusive global licencing agreement with NeraCare to develop and commercialize NeraCare’s Immunoprint test for guiding early-stage melanoma...
IN8bio (NASDAQ:INAB) shared updated data showcasing continued progression-free survival (PFS) from its Phase 1 trial of INB-100 in older patients with hematologic malignancies undergoing haploidentical stem cell...